Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
1 The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
2 Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
3 Breakthrough Breast Cancer Research Unit, Guy's Hospital Campus, Kings Health Partners, London SE1 9RT, UK
Breast Cancer Research 2012, 14:115 doi:10.1186/bcr3332
See related research by Byrski et al., http://breast-cancer-research.com/content/14/4/R110Published: 13 November 2012
A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is discussed.